Sagittarius Life Science Corp. (Taiwan, China)

The company was set up in March 1998. In July 2001, the company's products Saxobin (Doxazosinmesylate) tablets2mg was agreed for future reference by the Department of Health. Ref: DOH drug No. 0900039817. In October 2001, the company's products anti-osteoporosis drugs SO101C received grants the leading new product development from Industrial Development Bureau Ministry of Economic Affairs. In March 2002, the company products dementia long-term treatment of percutaneous absorption patch SA201D was patented by U.S. Patent numbers: US6352715B103/05/02. In April 2002, the company MG103 R & D results were published in Journal of Cellular Biochemistry 84 : 532-544 (2002 ). In August 2002, its shares went though public offering. In September 2002, anti-osteoporosis medicine SO101C was approved by Department of Health and granted formal entry into Phase II human clinical trials.